Compare VVV & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VVV | ARQT |
|---|---|---|
| Founded | 1866 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.3B |
| IPO Year | 2016 | 2020 |
| Metric | VVV | ARQT |
|---|---|---|
| Price | $33.62 | $22.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 7 |
| Target Price | ★ $39.53 | $31.86 |
| AVG Volume (30 Days) | ★ 1.5M | 1.2M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 1.86 | ★ 88.79 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,285,000,000.00 | $376,072,000.00 |
| Revenue This Year | $20.68 | $34.46 |
| Revenue Next Year | $10.61 | $29.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 9.64 | ★ 91.34 |
| 52 Week Low | $28.50 | $11.86 |
| 52 Week High | $41.33 | $31.77 |
| Indicator | VVV | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 33.94 | 35.75 |
| Support Level | $32.85 | $22.56 |
| Resistance Level | $36.65 | $27.26 |
| Average True Range (ATR) | 1.04 | 1.26 |
| MACD | -0.65 | -0.26 |
| Stochastic Oscillator | 10.48 | 3.25 |
Valvoline Inc provides automotive preventive maintenance through retail stores across the U.S. and Canada, offering approximately 15-minute stay-in-your-car oil changes, battery, bulb, and wiper replacements, tire rotations, and other manufacturer-recommended maintenance. Its full-service oil changes include Valvoline oil, a new oil filter, chassis lubrication, and an 18-point maintenance check. The Company provides differential fluid, fuel system cleaning, headlight and taillight replacement, radiator service, transmission service, air conditioning, and air filter replacement. It operates and franchises approximately 2,200 Valvoline Instant Oil Change and Valvoline Great Canadian Oil Change retail locations. The majority of revenue is generated from the United States of America.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.